Keros Therapeutics Inc.
Organization details
- Legal name
- Keros Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Lexington
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KROS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001664710
- EIN
- 81-1173868
Board of directors
-
Alpna Seth · DirectorSince 2023
-
Anne Prener · DirectorSince 2026
- Since 2023
-
Charles W. Newton · DirectorSince 2026
-
Jasbir Seehra · Director · CHIEF EXECUTIVE OFFICERSince 2023
- Since 2024
-
Julius Knowles · DirectorSince 2023
-
Mary Ann Gray · DirectorSince 2023
-
Nima Farzan · DirectorSince 2023
-
Ran Nussbaum · DirectorSince 2023
-
Tomer Kariv · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.5%
Board connections
9 of this board's directors also sit on 22 other boards. 22 are in the same sector.
-
Compass Therapeutics Inc. Same sectorvia Carl L. Gordon and Mary Ann Gray
-
ADARx Pharmaceuticals Inc. Same sectorvia Carl L. Gordon
-
Adicet Bio Inc. Same sectorvia Carl L. Gordon
-
ArriVent BioPharma Inc. Same sectorvia Carl L. Gordon
-
Ascendis Pharma A/S Same sectorvia Jean Jacques Bienaime
-
Bio-Techne Corp Same sectorvia Alpna Seth
-
BioMarin Pharmaceutical Inc. Same sectorvia Jean Jacques Bienaime
-
BlossomHill Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Coherus Oncology Inc. Same sectorvia Charles W. Newton
-
Damora Therapeutics Inc. Same sectorvia Anne Prener
-
Dr. Reddy's Laboratories Ltd Same sectorvia Alpna Seth
-
Electra Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Eloxx Pharmaceuticals Inc. Same sectorvia Tomer Kariv
-
Immunome Inc. Same sectorvia Jean Jacques Bienaime
-
Incyte Corp. Same sectorvia Jean Jacques Bienaime
-
LB Pharmaceuticals Inc Same sectorvia Ran Nussbaum
-
Latigo Biotherapeutics Inc. Same sectorvia Nima Farzan
-
MBX Biosciences Inc. Same sectorvia Carl L. Gordon
-
Novavax Inc. Same sectorvia Charles W. Newton
-
Palisade Bio Inc. Same sectorvia Mary Ann Gray
-
Scribe Therapeutics Inc. Same sectorvia Carl L. Gordon
-
UroGen Pharma Ltd. Same sectorvia Ran Nussbaum
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $75,770
- 6 purchases by 1 insider
- Sold, last 12 months
- $522,950
- 12 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2026 | Cho Esther Officer (Chief Legal Officer) | Open-market sale | −4,485 | $10.29 | $46,151 |
| Aug 18, 2026 | Charles W. Newton Director | Open-market sale | −551 | $10.30 | $5,675 |
| Aug 18, 2026 | Lerner Lorena Raquel Officer (Chief Scientific Officer) | Open-market sale | −3,568 | $10.29 | $36,715 |
| Aug 18, 2026 | Tanini Annita Officer (Corp. Controller & VP, Finance) | Open-market sale | −1,224 | $10.29 | $12,595 |
| Aug 17, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.27 | $10,270 |
| Jul 15, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.61 | $10,610 |
| Jul 1, 2026 | Anne Prener Director | Grant or award | +13,786 | — | — |
| Jun 15, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,000 | $10.19 | $10,190 |
| Jun 11, 2026 | Charles W. Newton Director | Open-market sale | −550 | $10.04 | $5,522 |
| Jun 4, 2026 | Nima Farzan Director | Open-market sale | −2,625 | $10.73 | $28,166 |
| Jun 4, 2026 | Julius Knowles Director | Open-market sale | −2,625 | $10.73 | $28,166 |
| Jun 4, 2026 | Alpna Seth Director | Open-market sale | −2,625 | $10.72 | $28,140 |
| Jun 3, 2026 | Alpna Seth Director | Grant or award | +7,142 | — | — |
| Jun 3, 2026 | Julius Knowles Director | Grant or award | +7,142 | — | — |
| Jun 3, 2026 | Mary Ann Gray Director | Grant or award | +7,142 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Keros Therapeutics Inc.
Who is the CEO of Keros Therapeutics Inc.?
Jasbir Seehra is Keros Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Keros Therapeutics Inc.'s board?
Keros Therapeutics Inc.'s board has 11 directors: Alpna Seth, Anne Prener, Carl L. Gordon, Charles W. Newton, Jasbir Seehra, Jean Jacques Bienaime, Julius Knowles, Mary Ann Gray, Nima Farzan, Ran Nussbaum and 1 other.
Are Keros Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Keros Therapeutics Inc. insiders bought $75,770 of shares in 6 purchases and sold $522,950 of shares in 12 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="keros-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.